Guillian Barre Syndrome
Dr. Ira Shah
Consultant Pediatrician, Nanavati Hospital and B.J.Wadia Hospital for Children, Mumbai India
First Created: 03/06/2001  Last Updated: 03/06/2001

Patient Education

What is Guillian Barre Syndrome?

Gillian Barre (pronounced as Gee-a-bare) syndrome is one of the causes of paralysis of both legs and hands of the body. It is also called as GBS.

Why does GBS occur?

GBS occurs due to an abnormal reaction of our own body’s immune system whereby the body’s immune system attacks the myelin (covering on the nerves) and thus leads to improper functioning of the nerves and thus weakness.

Who can get GBS?

GBS can occur in anyone. However who may get it is not known. Not all individuals who suffer from infection or had a vaccine shot get GBS. It depends on the patient's immune system and how the immune system reacts to these factors. Thus, one cannot predict who is more prone to get GBS.

What are the symptoms of GBS?

Children will initially have acute leg pain and stiffness. The child will refuse to walk and starts limping. Gradually weakness progresses rapidly in 2-4 weeks and there is an inability to move both upper and lower limbs and there may also be difficulty in eating and there may be nasal twang to the voice. In very severe cases, there may be difficulty in breathing due to the involvement of the respiratory muscles also.

How is the diagnosis of GBS made?

The doctor may suspect GBS on clinical evaluation. However other conditions such as poliomyelitis may also mimic similar symptoms and thus doctors may advise certain tests. These include nerve conduction velocity study (NCV) and even analysis of elevated protein content in the brain fluid (cerebrospinal fluid).

What is the treatment of GBS?

Treatment of GBS consists of support to respiration. If there is difficulty in breathing, the child may require ventilatory support - specific treatment in form of immunoglobulin (IVIG) may be given. In some centers, plasma exchange in form of plasmapheresis is done to remove abnormal circulating immune complexes.

What is the outcome of patients with GBS?

Patients with Guillain Barre syndrome usually recover on their own. Recovery is faster when treated with IVIG or plasmapheresis.

What are the complications of GBS?

Most of the time, GBS is self-limiting. However, in some patients, symptoms may persist for a long time and the disease may become chronic and lead to a condition called as CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). In patients with CIDP, weakness may follow a longer course but breathing problem usually does not arise. Patients with CIDP may need treatment with plasmapheresis, immunoglobulin, or steroids.

Sometimes, GBS can recur for the second time.

How long does it take for recovery to occur in GBS?

Usually, total recovery takes 2-3 months and in some patients may take a year. In patients with chronic disease, recovery may not be complete and there may be residual weakness, numbness, and pain.

Can a child with GBS be given vaccines?

A child with GBS should avoid immunization for at least 6 weeks after complete recovery. In some children, vaccines may have to be deferred for even a year.


1. Sladky J, Ashwal S. Inflammatory Neuriopathies. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, editors. Swaiman's Pediatric Neurology Principles and Practice. 5 ed. China: Elsevier Saunders; 2012. p. 1532-48.
2. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. The Journal of infectious diseases. 1997;176 Suppl 2:S92-8. Epub 1997/12/13.
3. Kinnunen E, Farkkila M, Hovi T, Juntunen J, Weckstrom P. Incidence of Guillain-Barre syndrome during a nationwide oral poliovirus vaccine campaign. Neurology. 1989;39(8):1034-6. Epub 1989/08/01.
4. Uhari M, Rantala H, Niemela M. Cluster of childhood Guillain-Barre cases after an oral poliovaccine campaign. Lancet. 1989;2(8660):440-1. Epub 1989/08/19.
5. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. American journal of epidemiology. 1979;110(2):105-23. Epub 1979/08/01.
6. Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon C, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PloS one. 2014;9(1):e82222. Epub 2014/01/10.
7. Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998;51(4):1110-5. Epub 1998/10/22.
8. Nguyen DK, Agenarioti-Belanger S, Vanasse M. Pain and the Guillain-Barre syndrome in children under 6 years old. The Journal of pediatrics. 1999;134(6):773-6. Epub 1999/06/04.
9. Bos AP, van der Meche FG, Witsenburg M, van der Voort E. Experiences with Guillain-Barre syndrome in a pediatric intensive care unit. Intensive care medicine. 1987;13(5):328-31. Epub 1987/01/01.
10. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). The New England journal of medicine. 1956;255(2):57-65. Epub 1956/07/12.
11. Yuki N, Hartung HP. Guillain-Barre syndrome. The New England journal of medicine. 2012;366(24):2294-304. Epub 2012/06/15.
12. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Annals of neurology. 1990;27 Suppl:S21-4. Epub 1990/01/01.
13. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet. 2005;366(9497):1653-66. Epub 2005/11/08.
14. Burns TM. Guillain-Barre syndrome. Seminars in neurology. 2008;28(2):152-67. Epub 2008/03/21.
15. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barre syndrome. Annals of neurology. 1990;28(1):65-9. Epub 1990/07/01.
16. Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology. 1985;35(8):1096-104. Epub 1985/08/01.
17. Zafeiriou DI, Kontopoulos EE, Katzos GS, Gombakis NP, Kanakoudi FG. Single dose immunoglobulin therapy for childhood Guillain-Barre syndrome. Brain & development. 1997;19(5):323-5. Epub 1997/07/01.
18. Shahar E, Shorer Z, Roifman CM, Levi Y, Brand N, Ravid S, et al. Immune globulins are effective in severe pediatric Guillain-Barre syndrome. Pediatric neurology. 1997;16(1):32-6. Epub 1997/01/01.
19. Yata J, Nihei K, Ohya T, Hirano Y, Momoi M, Maekawa K, et al. High-dose immunoglobulin therapy for Guillain-Barre syndrome in Japanese children. Pediatrics international : official journal of the Japan Pediatric Society. 2003;45(5):543-9. Epub 2003/10/03.
20. Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barre syndrome: a multicentre study. Archives of disease in childhood. 1996;74(4):281-7. Epub 1996/04/01.
21. Roodbol J, de Wit MC, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC. Long-term outcome of Guillain-Barre syndrome in children. Journal of the peripheral nervous system : JPNS. 2014;19(2):121-6. Epub 2014/05/28.


Guillian Barre Syndrome Guillian Barre Syndrome 08/01/2015
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0